Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...

FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

FILE - Packaging for AbbVie's drug, Humira. Humira-referenced biosimilars have been launched this year, but have thus far gained very little traction. (AP Photo/David J. Phillip, File) The blockbuster ...

As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...

The first of at least 8 adalimumab biosimilars has finally launched in the United States after being kept off the market for years due to settlement agreements with the maker of the reference product, ...

Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the drug—dubbed Cyltezo—has struggled to gain traction thanks ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...

Humira is a brand-name drug prescribed to treat rheumatoid arthritis, psoriatic arthritis, and more. It can remain unrefrigerated for up to 14 days, as long as the temperature doesn’t go above 77°F ...

AbbVie's growth prospects remain strong despite the impending decline in revenue from Humira, thanks to promising alternatives Skyrizi, Rinvoq, and the recently FDA-approved Linzess. The company's ...

The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a ...